- Pivot Pharmaceuticals attains prestigious CSE25 status
- Recent acquisitions have extended the company’s portfolio in the cannabis space
- Numerous pharmaceutical and nutraceutical products in development pipeline
Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) announced on March 19, 2018, that it has been named to the CSE25 Index (http://nnw.fm/Y9FJq). CSE25 is a conglomerate of the 25 largest companies by market capitalization listed on the Canadian Securities Exchange. This achievement adds to Pivot Pharmaceuticals’ status as a constituent of the CSE Composite Index, which provides a distinctly different risk/return profile than the broad Canadian equity market.
“With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated in the news release. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.”
In February 2018, Pivot Pharmaceuticals entered into a letter of intent for the acquisition of Agro-Biotech Inc., a cannabis cultivator located in Quebec. Agro-Biotech received its producer’s license on January 12, 2018. On completion of the proposed acquisition, Pivot will be able to conduct research and development and store cannabis derivatives not currently covered under ACMPR regulations. The company will also be in a position to process natural health products and export cannabis oils and concentrates to international markets, once it receives an export permit.
The company’s recent acquisitions also include Thrudermic, LLC, a company based in North Carolina that has developed a transdermal, lipid-based nano-dispersion technology for cannabinoid delivery. Pivot also acquired ERS Holdings, LLC in February 2018, a California-based company that holds patents for the production of powderized cannabis oil that can be added to beverages and baked goods.
Pivot Pharmaceuticals is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals through proprietary drug delivery technologies via medical cannabis product division Pivot Green Stream Health Solutions (“PGS”). In early February 2018, the company announced that it had filed three provisional patents for cannabinoid-based product delivery technologies with the U.S. Patent Office. These are for its innovative transdermal nanotechnology, inhalation and mucus topical delivery platforms. Its BiPhasix™ Transdermal Drug Delivery technology has been tested in clinical trials approved by both the FDA and EMA. This delivery platform provides significant advantages over oral delivery technologies.
Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://nnw.fm/QoAH2). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.
For more information, visit the company’s website at www.PivotPharma.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
